Vial’s Post

Explore the innovative world of ophthalmology clinical trials with Amy Del Medico, Vial’s VP of Ophthalmology, as she shares insights on electronic data capture, patient recruitment challenges, and selecting the right CRO partner for your trial. Watch the video here: https://lnkd.in/gRwcNSyW

Monotherapy or multiple therapies for newly diagnosed glaucoma patients? According to a new randomized, controlled trial published in the American Journal of Ophthalmology... It depends upon the initial IOP. The Glaucoma Intensive Treatment Study, randomized: 🔹 242 newly diagnosed mild to moderate glaucoma patients 🔹 aged 40-78 🔹 Untreated IOP median of 24 🔹 to either monotherapy (mostly topical prostaglandin) OR 🔹 multitherapy = topical PLUS laser trabeculoplasty (mostly SLT) Here is the link to the full article: https://lnkd.in/gX4rAKgb Results? The primary endpoint was visual field progression and projection/predicted end-of-life visual field. They found "the visual field outcomes were not overwhelmingly better in the multi-treatment group, but post hoc analysis showed definite benefit in patients with higher untreated IOP" Interpretation: ✅ No overwhelming difference in visual field outcomes for patients with initial IOPs < 24 ✅ Likely less visual field progression and a mild difference in end-of-life visual field for patients with initial untreated IOP > 24 Take home? ✳ Newly dx'd glaucoma patients with IOP > 24 may need multiple initial therapies, = topical + SLT. #optometry #optometrists #optometrist #eye #vision #optometrystudent

~93% of clinical trial sites expect to work on some sort of decentralized studies in the coming year. Read about the implications for ophthalmology studies in this article by Drs. George Magrath, Andrew D. Pucker, and Winston Posvar in Ophthalmology Times. https://lnkd.in/etsXvgRP _______________________ #ophthalmology #clinicaltrials #lifesciences

Opthea announced the publication of a scientific review in the peer-reviewed journal Ophthalmology and Therapy. The publication, "Vascular Endothelial Growth Factor (VEGF) C and D Signaling Pathways as Potential Targets for the Treatment of neovascular (wet) AMD," underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to prevent blood vessel growth and vascular leakage in the retina and deliver superior visual outcomes in wet AMD patients when combined with standard-of-care anti-VEGF-A therapies. Read press release here: https://lnkd.in/ez62P5NG We want to thank the authors: Ian Leitch Mike Gerometta David Eichenbaum @Robert Finger Nathan Steinle Megan Baldwin Access the full publication: https://lnkd.in/eu2-_Bdt #Opthea #maculardegeneration #AMDResearch #wetAMD #ophthalmology #medicaleducation #biopharma #eyehealth #retinaspecialists #sozinibercept

🔥Hot Clinical Trials in Ophthalmology 👁️Utility of Caronia Glaucoma Card vs Amsler Grid for Monitoring Patients With Advanced Glaucoma 📣In this study, the author compared the efficacy of a novel at-home Caronia Glaucoma Card (CGC) with that of the Amsler grid (AG) in monitoring patients with advanced glaucoma. Overall, a higher percentage of patients preferred using the CGC (60%) compared with the AG (16%), whereas the remaining patients found no difference. Patients who noticed a change in their scotoma were more likely to notice progression with the CGC than with the AG. Most patients were able to perform the test without difficulty, with only 7.5% of the patients having physical or cognitive limitations to performance. Anecdotally, patients were able to identify their scotoma with the CGC that corresponded well to Humphrey Visual Field testing. Although further validation is needed, the CGC may represent an alternative at-home screening test for patients with severe glaucoma. Source: Caronia Glaucoma Card Versus Amsler Grid for Monitoring Pati... : Journal of Glaucoma (lww.com) #glaucoma #ophthalmology #clinicaltrials #clinicalresearch Marcia Swank Firouzeh Rajabian, MD TFS HealthScience

Ophthopedia Update:Trends and Sociodemographic Patterns in Keratoconus Management 2015-2020: An American Academy of Ophthalmology IRIS® Registry Analysis: Investigate trends in keratoconus (KCN) treatment patterns and diagnosis age between 2015-2020 and evaluate sociodemographic associations with treatment approach. #Ophthalmology #ophthotwitter #eyecare

The global ophthalmology market is evolving, with glaucoma care at the forefront of innovation. In our latest blog, we explore the current European market landscape, uncover key treatment trends, and highlight the reimbursement environment that MedTech innovators need to know. Read the full blog https://lnkd.in/dXx6vp7T #medtech #glaucomacare #ophthalmology #medicalinnovation #healthcare #reimbursement #medtechinnovators

Thanks to curated #RWD, we're gaining insights into cataracts, which are the leading cause of vision loss in the U.S. Learn how our recent partnership with the FDA and the American Academy of Ophthalmology led to major findings surrounding #IOL use among young patients with cataracts: https://hubs.la/Q02zhLTz0

In patients with primary open-angle glaucoma (POAG) with myopia, microvascular dropout rate and angular circumference change over time are associated with ganglion cell inner plexiform layer (GCIPL) thinning, according to a cohort study published in the American Journal of Ophthalmology. These changes signal glaucomatous progression, which clinicians can identify using optical coherence tomography (OCT) and OCT-angiography (OCT-A), according to the report. Read more: https://brnw.ch/21wLGHU #PrimaryOpenAngleGlaucoma #POAG #Glaucoma #Myopia #EyeCare #MicrovascularDropoutRate #AngularCircumference #GCIPLThinning #OCT #OCTA #GlaucomaProgression #EyeHealth #Optometrist #Optometry

🎥 Join Dr. Peter Kaiser as he delves into the significant advancements in ophthalmic treatment with the introduction of Bayer | Ophthalmology 8 mg aflibercept. Discover how this higher dosage is making strides in patient care, allowing for extended treatment intervals and improved outcomes, especially for those with challenging cases. Dr. Kaiser shares his experiences and the promising results observed in two distinct patient groups, showcasing the drug's versatility and effectiveness. Tune in to gain valuable insights into this groundbreaking development in ophthalmology! #COPHY2024 #Aflibercept8mg #OphthalmologyInnovation #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #glaucoma #Surgicalretina #uveitis #neuropathy COPHy Congress